全球遗传代谢紊乱检测市场 – 行业趋势及 2030 年预测

遗传代谢紊乱检测市场分析及规模

心肌病、高血压、糖尿病和高胆固醇血症病例的增多推动了代谢综合征市场的发展。根据世界卫生组织的数据，每年至少有约 280 万人死于肥胖，约有 1700 万人死于心血管疾病。日常生活压力增加和营养不良、不健康生活方式的适应以及心脏病家族史等因素也推动了市场的增长。

Data Bridge Market Research 分析，遗传代谢紊乱检测市场预计到 2030 年将达到 11.2515 亿美元，即 2022 年为 6.034 亿美元，预计在 2023 年至 2030 年的预测期内复合年增长率为 8.1%。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的见解外，Data Bridge Market Research 策划的市场报告还包括深度专家分析、患者流行病学、管道分析、定价分析和监管框架。

遗传代谢紊乱检测市场范围和细分

Market Definition

Metabolic genetic testing is required to test the patients suffering from metabolic syndrome which are grouped diseases that occur together and surges the risk of stroke, heart disease, and type 2 diabetes. These conditions include abnormal cholesterol level, high blood sugar, excess body fat around the waist, and increased blood pressure.

Inherited Metabolic Disorders Testing Market Dynamics

Drivers

• Increasing Incidence of Metabolic Syndromes

In the recent times, it has been witnessed that the cases of diabetes have been growing, and numerous countries might face a potential metabolic disorder epidemic. Numerous industrial countries are worried with the chronic obesity epidemic, as the U.S. is ahead in the number of obese cases. The state of the economy worldwide has improved during the time, mostly in underdeveloped nations with a high frequency of metabolic illnesses. Governments are being urged by several researchers to take action and develop studies to lessen obesity and diabetes. According to the reports of CDC in 2022, around 37.3 million people have diabetes. Almost 96 million people aged 18 years or older suffer from prediabetes (approx.38.0% of the adult U.S. population) and 26.4 million people aged 65 years or older (48.8%) have prediabetes.Thus, these syndromes boost the testing market.

• Increase in Smoking Cases

In 2020, around 22.3% of the global population used tobacco, accounting for around 36.7% of all men and 7.8% of the women globally. Although certain low- and middle-income countries are witnessing a decline in smoking incidence, the emerging world is projected to continue to see a growth in smoking-related illnesses and fatalities because of the comparatively high population growth rate. In this regard, the market is increasing rapidly.

Opportunities

• Increasing Incidence of Chronic Diseases

Growing sedentary occupations, changing consumer preferences and busy lifestyles are largely affecting the world population's disease profile, particularly non-communicable diseases such as obesity and diabetes. The primary causes of metabolic disorders are decreased physical activity, and unhealthy eating habits and long working hours. According to World Health Organization (WHO) records, the incidence of chronic disease is anticipated to grow by over 57% globally, by the year 2020. Thus, this instigates the metabolic testing market.

• Increasing Launches By Several Organizations

There ve been wide and rapid launches by multiple market playersregarding the smooth testing of metabolic disorders that are boosting the market growth. For instance, Centogene N.V launched a panel for detection of rare metabolic disease in April 2019, which combines genetic and biochemical testing to offer the most comprehensive screening for rare metabolic conditions.

Restraints/Challenges

• High cost of Diagnostic Tests

There have been several tests that are immensely available for testing metabolic diseases. But these tests are of growing cost that is not afforded by several patients, mostly belonging to the lower economic groups. Therefore, it hampers the market growth.

This inherited metabolic disorders testing market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the inherited metabolic disorders testing market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In 2021, Eli Lilly and Company announced the acquisition of Protomer Technologies. Protomer's proprietary peptide- and protein-engineering platform is used to detect and synthesize molecules that can sense glucose and other endogenous modulators of protein activity.
• In 2020, Lumen announced the discovery of metabolism tracking wellness device which offers real time data with person’s breath and also helps in maintaining fitness, weight loss, and others.

Global Inherited Metabolic Disorders Testing Market Scope

遗传性代谢疾病检测市场根据疾病类型、治疗类型、给药途径和最终用户进行细分。这些细分市场之间的增长情况将帮助您分析行业中增长缓慢的细分市场，并为用户提供有价值的市场概览和市场洞察，帮助他们做出战略决策，确定核心市场应用。

疾病类型

• 赫勒综合征
• 尼曼匹克病
• 泰-萨克斯病
• 戈谢病
• 法布里病
• 克拉伯病
• 其他的

治疗类型

• 酶替代疗法
• 细胞移植
• 小分子治疗
• 底物还原疗法
• 基因治疗
• 药物治疗

给药途径

• 口服
• 肠外
• 其他的

终端用户

• 医院和诊所
• 诊断实验室
• 血库
• 诊断实验室
• 其他的

遗传代谢紊乱检测区域分析/见解

对遗传代谢紊乱检测市场进行了分析，并根据上述疾病类型、治疗类型、给药途径和最终用户提供了市场规模洞察和趋势。

遗传代谢紊乱检测市场报告涵盖的国家包括北美洲的美国、加拿大和墨西哥、欧洲的德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、亚太地区 (APAC) 的中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区 (APAC) 的其他地区、沙特阿拉伯、阿联酋、南非、埃及、以色列、中东和非洲 (MEA) 的其他地区、南美洲的巴西、阿根廷和南美洲其他地区。

由于代谢紊乱的发病率不断上升、医疗支出不断增加以及人们认识的不断提高，北美在遗传性代谢紊乱检测市场中占据主导地位。

由于人民的可支配收入水平不断提高以及肥胖症和其他疾病的发病率不断上升，预计亚太地区将在 2023 年至 2030 年的预测期内以最高的增长率增长。

报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。   

医疗保健基础设施增长安装基础和新技术渗透

遗传性代谢疾病检测市场还为您提供每个国家/地区资本设备医疗支出增长、遗传性代谢疾病检测市场不同类型产品的安装基数、使用生命线曲线的技术的影响以及医疗监管情景的变化及其对遗传性代谢疾病检测市场的影响的详细市场分析。数据涵盖 2011-2021 年的历史时期。

竞争格局和全球遗传代谢紊乱检测市场份额分析

遗传性代谢紊乱检测市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对遗传性代谢紊乱检测市场的关注有关。

遗传性代谢紊乱检测市场的一些主要参与者包括：

• 梅奥医学教育与研究基金会（MFMER）（美国）
• MGC Diagnostics Corporation（美国）
• 雅培（美国）
• Promega 公司 (美国)
• Alomone Labs（以色列）
• Bio-Rad Laboratories, Inc.（美国）
• 诺华公司（瑞士）
• AstaReal（瑞典）
• 再生元制药公司 (美国)
• Biophytis（英国）
• AbbVie Inc.（美国）
• 达能公司（法国）
• 辉瑞公司（美国）
• Abbvie Inc.（美国）
• 百时美施贵宝公司 (美国)
• Biogen（美国）
• 葛兰素史克公司 (英国)
• F. Hoffmann-La Roche Ltd.（瑞士）

SKU-57118